Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide, autologous transplant, and dendritic cell vaccine in multiple myeloma
ACTRN12613000344796Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide, dexamethasone and autologous tumor lysate-pulsed dendritic cells in multiple myeloma (MM) (4 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Time to disease progression. Started Dec 2007; status: active, not recruiting.
02
Drugs
lenalidomidedexamethasoneautologous tumor lysate-pulsed dendritic cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12613000344796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000344796.